CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
400 ug Brimonidine Implant +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00972374
NCT00972374Phase 2Completed
CompareCT.gov

Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function

Allergan·interventional·Posted Sep 4, 2009·Updated Apr 24, 2013

In Brief

A Phase 2 clinical trial evaluating 400 ug Brimonidine Implant, 200 ug Brimonidine Implant, and 1 other intervention for Rhegmatogenous Macula-off Retinal Detachment. Completed, enrolled 44 participants across 6 sites in 6 countries.

Detailed Summary

This study will evaluate the efficacy and safety of the Brimo PS DDS® Applicator System (200 μg and 400 μg brimonidine tartrate) on visual function in patients with previous rhegmatogenous macula-off retinal detachment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhegmatogenous Macula-off Retinal Detachment
CountriesIndia, Israel, Philippines, South Korea, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 4, 2009
Enrollment StartNov 1, 2009
Primary CompletionOct 1, 2010
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.8 years ago

Interventions

400 ug Brimonidine Implantdrug

400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.

200 ug Brimonidine Implantdrug

200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.

Sham (no implant)other

Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.